在急性心肌梗塞后早期启动Empagliflozin和Sacubitril/Valsartan:机制研究
Daina Martínez-Falguera1,2, Júlia Aranyó3, Gemma Ferrer-Curriu1,3
1ICREC Research Program Germans Trias i Pujol Research Institute (IGTP) Barcelona Spain.
Journal of the American Heart Association
|May 26, 2025
概括
早期的empagliflozin降低了心肌梗塞 (MI) 后的炎症,并改善了心脏痕组成. 萨库比特里尔/瓦尔萨坦的联合治疗进一步增强了左心室重塑,并降低了心室动脉冲动风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 翻译医学是一种翻译医学.
背景情况:
- 恩帕格利弗洛辛和萨库比特里尔/瓦尔萨坦是已知的心力衰竭治疗方法.
- 在心肌梗塞 (MI) 之后,它们的影响需要进一步研究.
- 这项研究研究了它们对心脏病后炎症,新陈代谢和心脏功能的影响.
研究的目的:
- 评估心肌梗塞 (MI) 后早期开始使用empagliflozin,有或没有sacubitril/valsartan.
- 评估对心脏病发作后的炎症,氧化应激,新陈代谢,纤维化,心脏功能和腹腔动脉障碍 (VT) 风险的影响.
- 利用猪模型对这些治疗干预措施进行全面分析.
主要方法:
- 幸存下来的24头猪被随机分配到对照组,empagliflozin或empagliflozin+sacubitril/valsartan组.
- 监测免疫反应,代谢概况和心脏功能.
- 通过电刺激和映射评估了心室动脉障碍 (VT) 的诱导性;进行了组织分析.
主要成果:
- 恩帕格利弗洛辛在MI后减少了循环白细胞和单细胞,增加了氧化的生物可用性和保护性肝脂.
- 恩帕格利弗洛辛还改善了心肌痕组成 (原III).
- 组合疗法增强了左心室顺应性,减少了痕原I,改善了电生理学重塑,并降低了静脉动脉诱导性.
结论:
- 在接受β抑制剂治疗的猪模型中,早期的empagliflozin减少了炎症,改善了心脏痕特征,但没有影响心脏功能或静脉瘤风险.
- 将萨库比特里尔/瓦尔萨坦添加到empagliflozin中,增强了左心室重塑和降低了静脉瘤诱导能力.
- 这些发现表明,联合疗法在治疗心脏病后并发症方面具有潜在的益处.
更多相关视频
14:19Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction
Published on: October 14, 2016
11.7K
18:11A Research Method For Detecting Transient Myocardial Ischemia In Patients With Suspected Acute Coronary Syndrome Using Continuous ST-segment Analysis
Published on: December 28, 2012
24.4K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
527
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
527
01:30Heart Failure V: Medical Management
34
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
34
01:30Acute Coronary Syndrome III: Diagnostic Studies
27
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
27
01:28Acute Coronary Syndrome IV: Interprofessional Care
34
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
34
01:30Acute Coronary Syndrome I: Introduction
85
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
85
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
357
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
357